ArticleBrain & NeuroRehabilitation2026
Investigating the Neuroprotective Effects of Peripheral Nerve Microcurrent Stimulation in a Mouse Model of Parkinson's Disease.
Article in Brain & NeuroRehabilitation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a neurodegenerative disorder characterized by neuroinflammation and motor dysfunction. Current treatments primarily provide symptomatic relief. Microcurrent (MC) stimulation has recently emerged as a promising noninvasive technique for Alzheimer's disease; however, its therapeutic potential in PD remains underexplored. This study investigated the effects of MC therapy in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of PD. Female C57BL/6 mice were divided into 3 groups: control, MPTP treated, and MPTP plus MC treated. A step-form waveform (5 V, 7 Hz base frequency with 44 kHz superposition) was applied for 4 weeks. Motor function was evaluated using rotarod and open field tests, and neuropathological changes were assessed by analyzing tyrosine hydroxylase, poly (ADP-ribose) polymerase (PARP), Toll-like receptor (TLR) proteins, caspase-3, and immunohistochemistry. MC therapy significantly improved motor activity in MPTP-treated mice, with increased latency to fall compared to the MPTP-only group. In the substantia nigra, the MC-treated mice had reduced tyrosine hydroxylase neuronal degradation and α-synuclein accumulation. Western blot analysis further revealed that the MC-treated mice had attenuated neuroinflammation by downregulating the TLR4 pathway and reducing PARP and cleaved caspase-3 expression. These findings suggest that MCs preserve dopaminergic neurons by suppressing neuroinflammation in a mouse model of PD, highlighting their potential as a therapeutic modality for PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.